Dr Thomas Foltynie

Dr Thomas FoltynieTel: 020 3448 8726
Fax: 020 3448 8642
Email: tom.foltynie@nhs.net

National Hospital for Neurology and Neurosurgery

Movement disorders, Neurology and neurosurgery

Professional background

Thomas Foltynie is a Consultant Neurologist and Senior Lecturer at the National Hospital for Neurology & Neurosurgery. As well as seeing General Neurology patients, he has a specific interest in patient's with Movement Disorders. Tom did his PhD studying the epidemiology and genetics of Parkinson's disease and is now responsible for patients undergoing Deep Brain Stimulation for Parkinson's and other conditions.
He is also involved in trials of new treatments for Parkinson's disease including Duodopa, Exenatide and cell transplantation. He is on the scientific committe for the Cure Parkinson's Trust and the Data Monitoring Committee for "Prosavin" Gene Therapy for Parkinson's disease.

Research interests

  • Parkinson's disease
  • Dystonia
  • Tourette syndrome
  • Atypical forms of tremor


MRI-guided STN DBS in Parkinson’s disease without microelectrode recording:efficacy and safety. Foltynie T et al. Journal of Neurology, Neurosurgery & Psychiatry. 2010 in press.   
Surgical Management for Parkinson's disease. Foltynie T, Hariz M. Expert Rev Neurother. 2010 10(6) 903-14.   
The two cognitive syndromes of Parkinson’s Disease: 5 year follow-up of the CamPaIGN cohort Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne CE, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA.. Brain 2009. Nov;132(Pt 11):2958-69..   
Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive life-threatening dystonia. Martinez-Torres I, Limousin P, Tisch S, Page R, Pinto A, Foltynie T, Bhatia KP, Hariz MI, Zrinzo L.Mov Disord. 2009 Aug 15;24(11):1710-2.   
Improvement of tics after subthalamic nucleus deep brain stimulation. Martinez-Torres I, Hariz MI, Zrinzo L, Foltynie T, Limousin P. Neurology. 2009 May 19;72(20):1787-9    Current Issues in Parkinson’s Disease. Foltynie T. & Hewitt J. Geriatric Medicine 2. May 2009 13-17.   
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA. J Neurol. 2009 Mar;256(3):493-8    No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. Williams-Gray C, Goris A, Foltynie T, Compston A, Sawcer S, Barker RA. J Neurol. 2009 Jan;256(1):132-3.   
BDNF val66met Influences Time To Onset Of Levodopa-Induced Dyskinesia In Parkinson's Disease. Foltynie et al. JNNP 2009 Feb;80(2):141-4.   
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Goris A, Williams-Gray C, Clark G, Foltynie T et al. Ann Neurol. 2007 Aug;62(2):145-53.    
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.  Brain. 2007 Jul;130(Pt 7):1787-98. Williams-Gray C, Foltynie T et al.   
Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease. J Neurol. 2007 Jul;254(7):846-8. Goris A, Williams-gray C, Foltynie T et al.   
A case of voltage-gated potassium channel antibody-related limbic encephalitis. Harrower T, Foltynie T et al. Nat Clin Pract Neurol. 2006 Jun;2(6):339-43.    
The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort. Foltynie T, Matthews FE, Ishihara L, Brayne C; MRC CFAS. BMC Neurol. 2006 Aug 22;6:29.    
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. CNS Drugs. 2006;20(6):477-505.    
No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. Goris A, Williams-Gray CH, Foltynie T et al. Am J Hum Genet. 2006 Jun;78(6):1088-90.    
Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. Williams-Gray CH, Goris A, Foltynie T et al. J Neurol Neurosurg Psychiatry. 2006 May;77(5):665-7.   
No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. Williams-Gray CH, Goris A, Foltynie T et al. Mov Disord. 2006 Mar 21.    
Saccadic latency distributions in Parkinson's disease and the effects of L: -dopa. Michell AW, Xu Z, Fritz D, Lewis SJ, Foltynie T et al. Exp Brain Res. 2006 Mar 17.    
UCHL-1 is not a Parkinson's disease susceptibility gene. Healy DG, Abou-Sleiman PM, Casas JP, Ahmadi KR, Lynch T, Gandhi S, Muqit MM, Foltynie T et al. Ann Neurol. 2006 Apr;59(4):627-33.    
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Pyle A, Foltynie T et al. Ann Neurol. 2005 Apr;57(4):564-7.    
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. Foltynie T et al. J Neurol. 2005 Jul;252(7):833-8.    
A genome wide linkage disequilibrium screen in Parkinson's disease. Foltynie T et al. J Neurol. 2005 May;252(5):597-602.    
Planning Ability in Parkinson's disease is influenced by the COMT val(158)met polymorphism. Foltynie T et al. Mov Disord. 2004 Aug;19(8): 885-91.   
Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. Lewis SJ, Foltynie T et al. J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):343-8.    
Biomarkers and Parkinson's disease. Michell A, Lewis, S, Foltynie T, Barker RA. Brain 2004 Aug,127(Pt8):1693-705.    
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The Campaign study. Foltynie T et al. Brain 2004 Mar;127(Pt3):550-60.   
Future Challenges in Parkinson's disease. Foltynie T. Barker R.A. J. Neurol 2004 Mar;251(3):361-5.    
Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson's disease. Burnstein, RM, Foltynie T et al. Int J Biochem Cell Biol 2004 Apr;36(4): 702-13.    
A whole genome association study in multiple sclerosis patients from north Portugal. B.Silva, T.Thorlacius, K.Benediktsson, C.Pereira, R.Fossdal, H.Jonsson, A.Silva, I.Leite, J.Cerqueira, P.Costa, M.Marta, T.Foltynie, S.Sawcer, A.Compston, A.Jonasdottir. J.Neuroimmunol. 2003 Oct;143(1-2):116-9   
A genome-wide screen for association in Hungarian multiple sclerosis. C.Rajda, K. Bencsik, E.Seres, A.Jonasdottir, T.Foltynie, S.Sawcer, K.Benediktsson, R.Fossdal, E.Setakis, A.Compston, L.Vécsei. J.Neuroimmunol. 2003 Oct;143(1-2):84-7   
How common is dementia with Lewy bodies? Barker R.A. Foltynie T. J. Neurol. Neurosurg. Psychiatry 2003;74:697-698   
The Genetic Basis of Parkinson's disease. Foltynie; T. Sawcer; S. Brayne; C.E.G. Barker; R.A. J. Neurol. Neurosurg. Psychiatry 2002; 73;4: 363-7   
The Heterogeneity of Idiopathic Parkinson's Disease. Foltynie, T. Brayne, C.E.G. Barker, R.A. J. Neurol. 249 (2002) 2, 138-145.   
Vascular Parkinsonism. A Review of the Frequency and Precision of the diagnosis. Foltynie,T. Barker, R.A., Brayne, C.E.G. Neuroepidemiology 2002;21:1-7.

GMC/GDC number: 4208950